Trial intelligence / Profile preview

Timing of premixed lispro 25/75 injection and glucose profiles in newly diagnosed type 2 diabetes

ChiCTR1800015828Phase 4Recruiting

Sponsor
Nanjing First Hospital
Start
Apr 2018
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of insulin lispro in type 2 diabetes mellitus (T2DM), sponsored by Nanjing First Hospital. Primary endpoint: Mean blood glucose. Started Apr 2018; status: recruiting.

02

Drugs

insulin lispro
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on ChiCTR1800015828.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR1800015828.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call